Physician profile
Lalitha Sunder
NPI 1851395438
$24,594.43
in general payments reported to CMS, 2019-2025
45 companies · $2,796 in 2025
The $2,796 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $543 · 2021: $729 · 2022: $3,290 · 2023: $2,796 · 2024: $12K · 2025: $2,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,376 · Food and Beverage: $8,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,375.91 |
| Food and Beverage | $8,637.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,161.32 | 2022-2025 | Symplicity G3, Onyx Frontier, Corevalve Evolut R |
| Abbott Laboratories | $1,670.06 | 2019-2025 | Aveir, Mitraclip, Precision Xtra |
| Boston Scientific Corporation | $1,297.37 | 2019-2025 | Avvigo Guidance System, Watchman Flx, Comet |
| Abiomed | $1,056.35 | 2022-2025 | Impella |
| Amgen INC. | $983.78 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $875.95 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $875.78 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $673.71 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $671.85 | 2021-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $649.46 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $634.85 | 2020-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $507.79 | 2019-2025 | |
| Medtronic Vascular, INC. | $301.41 | 2019 | |
| Lilly USA, LLC | $292.16 | 2022-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $279.81 | 2021-2025 | Nexletol |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalitha Sunder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.